Arqt did fda approve drug today

Yes, Arcutis Biotherapeutics (ARQT) received FDA approval for the expanded use of Roflumilast Cream 0.15% to treat atopic dermatitis (AD) in adults and children as young as age 6. This approval is a significant catalyst for the company, as it expands the indication for the drug beyond its initial approval for plaque psoriasis in 2022 and its recent approval for seborrheic dermatitis in 2023. The FDA decision on Roflumilast Cream 0.15% was expected on July 7, 2024, so today's approval is in line with that anticipated timeline.